A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
=== Neuronal proliferation === NGF can drive the expression of genes such as bcl-2 by binding to the Tropomyosin receptor kinase A, which stimulates the proliferation and survival of the target neuron. High affinity binding between proNGF, sortilin, and p75NTR can result in either survival or programmed cell death (PCD). Study results indicate that superior cervical ganglia neurons that express both p75NTR and TrkA die when treated with proNGF, while NGF treatment of these same neurons results in survival and axonal growth. Survival and PCD mechanisms are mediated through adaptor protein binding to the death domain of the p75NTR cytoplasmic tail. Survival occurs when recruited cytoplasmic adaptor proteins facilitate signal transduction through tumor necrosis factor receptor members such as TRAF6, which results in the release of nuclear factor κB (NF-κB) transcription activator. NF-κB regulates nuclear gene transcription to promote cell survival. Alternatively, programmed cell death occurs when TRAF6 and neurotrophin receptor interacting factor (NRIF) are both recruited to activate c-Jun N-terminal kinase (JNK); which phosphorylates c-Jun. The activated transcription factor c-Jun regulates nuclear transcription via AP-1 to increase pro-apoptotic gene transcription.
=== Status epilepticus === Status epilepticus may be defined as seizure activity lasting beyond five minutes and needing anticonvulsant medication. Several guidelines recommend the use of propofol for the treatment of refractory status epilepticus.
=== Initiation === Initiation involves the small subunit of the ribosome binding to the 5' end of mRNA with the help of initiation factors. The ribosome and its associated factors assemble and bind to an mRNA. The first TRNA is attached at the start codon. This process is defined as either cap-dependent, in which the ribosome binds initially at the 5' cap and then travels to the stop codon, or as cap-independent, where the ribosome does not initially bind the 5' cap. The 5' cap is added when the nascent pre-mRNA is about 20 nucleotides long.
Collins began self-harming as a teenager and did so until her early thirties. The first time she engaged in self-harm was at the age of 13 when she picked up a knife and cut her hand in front of her parents. In 2004, Collins had an abortion when she was around three months pregnant after doctors told her that her baby would most likely be born intersex and was therefore advised to terminate the pregnancy. Following this, she discovered that her then boyfriend, a stockbroker, with whom she had been together with for several years, was having an affair, resulting in the break down of their relationship. Collins recalled an incident where she slashed her hand open with a kitchen knife to deal with the pain of "grieving for [her] baby and [her] relationship". She also suffered from anxiety attacks and began binge-eating. Collins suffers from polycystic ovary syndrome and in January 2012, she suffered a miscarriage and gave birth to a four and a half month old foetus on her landing the day before she attended the 17th National Television Awards. In July 2020, Collins suffered a third miscarriage, which she initially suspected to be a heavy period, after which she wrote an open letter to Meghan, Duchess of Sussex detailing her struggles with infertility and thanking her for her "bravery and honesty" for opening up about her own miscarriage. Collins previously admitted her fear about never becoming a mother but has said she "won't give up hope" and hopes to conceive naturally one day.
Sources: en.wikipedia.org
==== Other procedures ==== Orthokeratology is a method using specialized hard or rigid gas-permeable contact lenses to transiently reshape the cornea in order to improve the refractive state of the eye or reduce the need for eyeglasses and contact lenses. In 2009, researchers at the University of Pittsburgh Medical center demonstrated that stem cell collected from human corneas can restore transparency without provoking a rejection response in mice with corneal damage. For corneal epithelial diseases such as Stevens Johnson Syndrome, persistent corneal ulcer etc., the autologous contralateral (normal) suprabasal limbus derived in vitro expanded corneal limbal stem cells are found to be effective as amniotic membrane based expansion is controversial. For endothelial diseases, such as bullous keratopathy, cadaver corneal endothelial precursor cells have been proven to be efficient. Recently emerging tissue engineering technologies are expected to be capable of making one cadaver-donor's corneal cells be expanded and be usable in more than one patient's eye. One such technique has been reported to be safe and efficacious in a clinical pilot study with long term follow-up.
Deficient scar formation: Results in wound dehiscence or rupture of the wound due to inadequate formation of granulation tissue. Excessive scar formation: Hypertrophic scar, keloid, desmoid. Exuberant granulation (proud flesh). Deficient contraction (in skin grafts) or excessive contraction (in burns). Pigmentary changes such as Postinflammatory hyperpigmentation Others: Dystrophic calcification, painful scars, incisional hernia Other complications can include infection and Marjolin's ulcer.
== Immunoglobulin-like receptors == Glycoprotein VI Receptor GPVI belongs to immunoglobulin family of glycoproteins. It consists of two extramembrane immunoglobulin domains, which are associated with extracellular glycosylated mucine and together they form a stalk. Another part of the receptor consists of transmembrane helix with a short cytosolic domain. A FcRγ chain with ITAM (immunoreceptor tyrosine-based activation motif) domain is associated with the transmembrane domain. The short cytosolic domain interacts with calmodulin and Src kinases Lyn and Fyn. These Src kinases phosphorylate tyrosine in ITAM domain and activate a signalling cascade. Glycoprotein VI belongs to collagen receptors that are primarily expressed on platelets surface. Together with integrin receptor α2β1 they provide coagulation cascade activation when a blood-vessel is damaged. When damage occurs, endothelial collagen is uncovered and is bound by GPVI receptor on platelets. This interaction activates signalling cascades leading to coagulation factors release. Mainly fibrillar collagens type I and III serve as ligands. Functions include: Platelet adhesion and activation - the most important platelet collagen receptor in terms of signaling. LAIR1(Leukocyte-associated IG-like receptor) works as inhibition signal for different immune cells. Lair-1 consists of Ig domain, transmembrane helix and a short cytosolic domain, which includes two inhibition motifs (ITIMs), which can block tyrosine domain when activated.
Half a Life is a 2001 novel by Nobel laureate V. S. Naipaul published by Alfred A. Knopf. The novel is set in India, Africa and Europe (London, Berlin and Portugal). Half a Life was long listed for the Booker prize (2001).
On June 28, the Senate voted on a procedural motion to begin debate on the bill. Initially, fiscal conservatives Ron Johnson and Rand Paul, along with moderate Thom Tillis, voted against the motion, while fiscal conservatives Rick Scott, Mike Lee, and Cynthia Lummis, as well as moderate Lisa Murkowski, withheld their votes. After hours of negotiations, which resulted in Alaska specific provisions for Murkowski and Republican leadership support for an amendment vote that would result in increased Medicaid cuts targeted at the fiscal conservatives, Johnson, Scott, Lee, Lummis and Murkowski voted for the motion. The passage of the motion to proceed began the "vote-a-rama" process, in which senators can propose an unlimited number of amendments to the bill. Before it could begin, Democrats required the clerks of the Senate to read the entire 940 page bill in order to highlight Medicaid cuts. The vote-a-rama began two days later, on June 30, in the early morning. One of the few successful amendment votes, passing 99–1, removed the proposed AI law moratorium. The vote-a-rama set a record for the most amendment votes in Senate history. After an over 24-hour vote-a-rama, the bill passed the Senate on July 1, 2025, in a mostly party-line 51–50 vote. All Senate Democrats voted against the bill, and Republicans Rand Paul, Thom Tillis, and Susan Collins of Maine broke from their party to vote against the bill as well. Faced with a tie vote, Republican vice president JD Vance cast a tie-breaking vote in favor of the bill.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.